4 research outputs found
A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
BACKGROUND: The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem for public health, affecting both developed and developing countries. Impaired fasting plasma glucose has been previously associated with endothelial dysfunction, higher levels of inflammatory markers and increased risk of developing insulin resistance and cardiovascular events. Besides life-style changes, the blockade of the renin-angiotensin system has been proposed as a useful alternative intervention to improve insulin resistance and decrease the number of new type-2 diabetes cases. The aim of this clinical trial is to study the effect of the treatment with Candesartan, an angiotensin II receptor antagonist, on the insulin resistance, the plasma levels of adipoquines, oxidative stress and prothrombotic markers, in a group of non diabetic, non hypertensive, dysglycemic and obese subjects. METHODS AND DESIGN: A randomized, double blind, cross-over, placebo-controlled, clinical trial was designed to assess the effects of Candesartan (up to 32 mg/day during 6 months) on the Homeostasis Model Assessment (HOMA) index, lipid profile, protrombotic state, oxidative stress and plasma levels of inflammatory markers. The participants will be recruited in the "Fundaci贸n Cardiovascular de Colombia". Subjects who fullfil selection criteria will receive permanent educational, nutritional and exercise support during their participation in the study. After a 15 days-run-in period with placebo and life-style recommendations, the patients who have a treatment compliance equal or greater than 80% will be randomlly assigned to one of the treatment groups. Group A will receive Candesartan during 6 months and placebo during 6 months. Group B will receive placebo during the first 6 months, and then, Candesartan during the last 6 months. Control visits will be programed monthly and all parameters of interest will be evaluated every 6 months. HYPOTHESIS: Treatment with Candesartan, could improve the HOMA index, the response to the oral glucose tolerance test and reduce the plasma levels of adipoquines, oxidative stress and prothrombotic markers, in non diabetic, non hypertense subjects with dysglycemia and abdominal obesity, recruited from a population at high risk of developing insulin resistance. These effects are independent of the changes in arterial blood pressure. Trial registration: NCT0031920
Neoplasia endocrina m煤ltiple tipo-2B
La neoplasia endocrina multiple tipo 2 comprende
tres sindromes : la neoplasia endocrina m煤ltiple
2A con predisposici贸n gen茅tica para desarrollar
carcinoma medular del tiroides,
feocromocitoma e hiperplasia primaria de
paratiroides. La neoplasia endocrina m煤ltiple 2B,
desorden autos贸mico dominante con feocromocitoma
y carcinoma medular del tiroides que
generalmente se presenta a una edad m谩s temprana
y es m谩s agresivo que la de tipo 2A, por
lo que su diagn贸stico precoz es cr铆tico; estos
pacientes, que tambi茅n presentan neuromas
mucosos, ganglioneuromas intestinales y h谩bito
marfanoide, no desarrollan hiperparatiroidismo.
Y el carcinoma medular familiar del tiroides, sin
ninguna otra manifestaci贸n cl铆nica de neoplasia
endocrina m煤ltiple 2A o 2B.
Se han identificado mutaciones activadoras del
proto-oncogene RET en todas las variantes de
la neoplasia endocrina m煤ltiple tipo 2. Las mutaciones
del RET en la neoplasia endocrina m煤ltiple
2B ocurren principalmente (95%) en las
regiones que codifican para el dominio de tirosina
cinasa, en los codones 883 y 918.
No obstante las m煤ltiples modalidades de tratamiento
para los c谩nceres tiroideos, especialmente
para el carcinoma medular, la sobrevida de los
pacientes afectados no ha mejorado. Por tanto
el desarrollo de nuevas estrategias de tratamiento,
inclu铆da la terapia g茅nica, parece esperanzador
para estos pacientes. La clonaci贸n de los cotrasportadores
sodio-yoduro, ha abierto una nueva
puerta para la terapia g茅nica citorreductiva
basada en la transferencia gen茅tica de los cotrasportadores,
seguida por la ablaci贸n con yodo
radiactivo (131I).
Presentamos un caso espor谩dico de neoplasia聽
endocrina m煤ltiple 2B en una ni帽a asociado a
una mutaci贸n en el cod贸n 918 del ex贸n 16 del
proto-oncogene RET